Merck

Merck establishes R&D headquarters in China

Tuesday, December 6, 2011 01:10 PM

Merck, known as MSD outside the United States and Canada, has established an Asia research & development headquarters for innovative drug discovery and development located in Beijing, China. The new facility is part of a $1.5 billion commitment the company has made to invest in R&D in China over the next five years.

More... »

Rhythm names chief scientific officer

Wednesday, November 30, 2011 12:40 PM

Rhythm has named Lex Van der Ploeg, PhD, chief scientific officer. Van der Ploeg brings to Rhythm more than 25 years of drug development experience in obesity, metabolic diseases, and other therapeutic areas.

More... »

Gilead Sciences acquires Pharmasset, looks to duplicate its HIV success in hepatitis C

Monday, November 28, 2011 08:02 AM

Consolidation among drug sponsors continues. 

More... »

Bend Research signs licensing agreement with Merck

Wednesday, November 16, 2011 02:49 PM

Bend Research, an independent drug-formulation development and manufacturing company, has entered into a licensing agreement with Merck, through a subsidiary.

More... »

Ablynx, Merck expand partnership

Wednesday, November 9, 2011 03:08 PM

Ablynx has further expanded its relationship with Merck Serono and entered into a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis. The companies will exploit the unique Nanobody features and will develop multi-specific products, which have extended half-lives.

More... »

Rhythm names CEO

Wednesday, November 9, 2011 08:34 AM

Rhythm, a biotechnology company, has named Keith M. Gottesdiener, MD, chief executive officer.

More... »

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011 11:26 AM

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Kaiser joins Covance

Wednesday, October 19, 2011 10:48 AM

Covance has named Raymond Kaiser, Ph.D., global science leader and vice president for biotechnology services. Kaiser will replace Dr. Carl Martin, who will be retiring from this role, after 35 years with Covance.

More... »

Merck, Ono Pharmaceutical collaborate

Tuesday, October 4, 2011 01:33 PM

Merck Serono has signed two separate agreements with Ono Pharmaceutical, Osaka, Japan to strengthen its multiple sclerosis and cancer franchises.

More... »